The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
Completed · Phase 3 · Has a placebo group
Conditions studied: Alzheimer Disease
In brief
The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will determine if measures of clinical stabilization produced by memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS measures of brain NAA and MRI volumetric measures of hippocampal volume.
Key facts
- Study ID
- NCT00255086
- Run by
- Stanford University
- People needed
- 17
- Starts
- 2005-05-01
- Expected to finish
- 2010-02-01
- Last updated by the study team
- 2017-04-07
Who can join
Age: 50 and older, up to 95. Sex: any. Healthy volunteers: not accepted.
Where it is running
- VA Palo Alto Health Care System — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.